theory clinical_46_8
imports Main

begin

typedecl entity
typedecl event

consts
  PARPInhibitors :: "entity ⇒ bool"
  DoubleStrandBreaks :: "entity ⇒ bool"
  SingleStrandBreakRepair :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Prevent :: "event ⇒ bool"
  Force :: "event ⇒ bool"
  Rely :: "event ⇒ bool"
  HomologousRecombinationRepair :: "entity ⇒ bool"
  NonHomologousEndJoining :: "entity ⇒ bool"
  Repair :: "event ⇒ bool"
  DNA :: "entity ⇒ bool"
  SyntheticLethality :: "entity ⇒ bool"
  GeneticEvents :: "entity ⇒ bool"
  LossOfPALB2 :: "entity ⇒ bool"
  Occur :: "event ⇒ bool"
  CoOccurrence :: "event ⇒ bool"
  Result :: "event ⇒ bool"
  CellDeath :: "entity ⇒ bool"
  Mechanism :: "entity ⇒ bool"
  Damage :: "entity ⇒ bool"
  Cells :: "entity ⇒ bool"
  PARP1Inhibition :: "entity ⇒ bool"
  Lead :: "event ⇒ bool"
  Combine :: "event ⇒ bool"
  Depend :: "event ⇒ bool"
  Inadequate :: "entity ⇒ bool"
  TherapeuticWindow :: "entity ⇒ bool"
  Patients :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  DueTo :: "event ⇒ bool"
  Create :: "event ⇒ bool"
  Benefit :: "event ⇒ bool"
  Source :: "event ⇒ entity ⇒ bool"

(* Explanation 1: PARP inhibitors cause replication‐associated double-strand breaks by preventing single-strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)
axiomatization where
  explanation_1: "∃x y z e1 e2 e3 e4. PARPInhibitors x ∧ DoubleStrandBreaks y ∧ SingleStrandBreakRepair z ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Prevent e2 ∧ Agent e2 x ∧ Patient e2 z ∧ Force e3 ∧ Agent e3 x ∧ Patient e3 y ∧ Rely e4 ∧ Agent e4 y ∧ HomologousRecombinationRepair z ∧ NonHomologousEndJoining z ∧ Repair e4 ∧ DNA z"

(* Explanation 2: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of PALB2, results in cell death due to the reliance on a singular mechanism to repair cumulative DNA damage. *)
axiomatization where
  explanation_2: "∃x y z e1 e2 e3. SyntheticLethality x ∧ GeneticEvents y ∧ LossOfPALB2 z ∧ Occur e1 ∧ Agent e1 x ∧ CoOccurrence e2 ∧ Agent e2 y ∧ Result e3 ∧ Agent e3 y ∧ Patient e3 z ∧ CellDeath z ∧ Rely e3 ∧ Mechanism z ∧ Repair e3 ∧ Damage z ∧ DNA z"

(* Explanation 3: The loss of PALB2 in cells can lead to synthetic lethality when combined with PARP1 inhibition, as it forces cells to depend on a singular, often inadequate, DNA repair mechanism, leading to cell death. *)
axiomatization where
  explanation_3: "∃x y z e1 e2 e3 e4. LossOfPALB2 x ∧ Cells y ∧ SyntheticLethality z ∧ PARP1Inhibition z ∧ Lead e1 ∧ Agent e1 x ∧ Patient e1 z ∧ Combine e2 ∧ Agent e2 x ∧ Patient e2 z ∧ Force e3 ∧ Agent e3 x ∧ Patient e3 y ∧ Depend e4 ∧ Agent e4 y ∧ Mechanism z ∧ Repair e4 ∧ Inadequate z ∧ CellDeath z"

(* Explanation 4: When cells with a loss of PALB2 rely on a singular DNA repair mechanism due to PARP1 inhibition, this can create a therapeutic window where patients may benefit from the treatment, as the inadequate repair mechanism leads to cell death. *)
axiomatization where
  explanation_4: "∃x y z w e1 e2 e3 e4 e5. Cells x ∧ LossOfPALB2 x ∧ Mechanism y ∧ PARP1Inhibition z ∧ TherapeuticWindow w ∧ Patients y ∧ Treatment z ∧ Rely e1 ∧ Agent e1 x ∧ Patient e1 y ∧ DueTo e2 ∧ Agent e2 x ∧ Patient e2 z ∧ Create e3 ∧ Agent e3 x ∧ Patient e3 w ∧ Benefit e4 ∧ Agent e4 y ∧ Source e4 z ∧ Lead e5 ∧ Agent e5 y ∧ Patient e5 z ∧ CellDeath z"

theorem hypothesis:
  assumes asm: "Patients x ∧ LossOfPALB2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z"
  (* Hypothesis: Patients with loss of PALB2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA. *)
  shows "∃x y z e1 e2 e3. Patients x ∧ LossOfPALB2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z ∧ Benefit e1 ∧ Agent e1 x ∧ Source e1 y ∧ Cause e2 ∧ Agent e2 z ∧ Rely e3 ∧ Agent e3 x ∧ Mechanism z ∧ Repair e3 ∧ Damage z ∧ DNA z"
proof -
  (* From the known information, we have the conditions for patients, loss of PALB2, PARP1 inhibition, and synthetic lethality. *)
  from asm have "Patients x ∧ LossOfPALB2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z" by meson
  
  (* Explanation 3 and the logical relation Implies(And(G, I), J) allow us to infer reliance on a singular DNA repair mechanism. *)
  then have "Rely e3 ∧ Agent e3 x ∧ Mechanism z ∧ Repair e3 ∧ Damage z ∧ DNA z" sledgehammer
  
  (* Explanation 4 and the logical relation Implies(And(G, I), K) allow us to infer a therapeutic window and benefit from treatment. *)
  then have "Benefit e1 ∧ Agent e1 x ∧ Source e1 y" <ATP>
  
  (* We also know from explanation 2 that synthetic lethality causes cell death, which is part of the causal chain. *)
  then have "Cause e2 ∧ Agent e2 z" <ATP>
  
  (* Combining these inferences, we can conclude the hypothesis. *)
  then show ?thesis <ATP>
qed

end
